Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.

Lawasut P, Groen RW, Dhimolea E, Richardson PG, Anderson KC, Mitsiades CS.

Semin Oncol. 2013 Oct;40(5):537-48. doi: 10.1053/j.seminoncol.2013.07.010. Review.

PMID:
24135398
2.

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, Tassone P.

Curr Drug Targets. 2013 Sep;14(10):1144-9. Review.

PMID:
23834146
3.

Insights from the gene expression profiling of multiple myeloma.

Claudio JO, Masih-Khan E, Stewart AK.

Curr Hematol Rep. 2004 Jan;3(1):67-73. Review.

PMID:
14695854
4.

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

Stewart AK, Fonseca R.

J Clin Oncol. 2005 Sep 10;23(26):6339-44. Review.

PMID:
16155017
5.

Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.

Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paíno T, Delgado M, Aires A, Ocio EM, García-Sanz R, San Miguel JF, Gutiérrez NC.

Haematologica. 2013 Apr;98(4):640-8. doi: 10.3324/haematol.2012.070011. Epub 2012 Oct 25.

6.

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.

Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A.

Oncogene. 2005 Apr 7;24(15):2461-73.

PMID:
15735737
7.

Gene expression profiling and multiple myeloma.

Shaughnessy J Jr, Zhan F, Barlogie B, Stewart AK.

Best Pract Res Clin Haematol. 2005;18(4):537-52. Review.

PMID:
16026736
8.

Genomic heterogeneity in multiple myeloma.

Szalat R, Munshi NC.

Curr Opin Genet Dev. 2015 Feb;30:56-65. doi: 10.1016/j.gde.2015.03.008. Epub 2015 May 16. Review.

PMID:
25982873
9.

Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma.

Claudio JO, Stewart AK.

Am J Pharmacogenomics. 2005;5(1):35-43. Review.

PMID:
15727487
10.

NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.

McCarthy BA, Yang L, Ding J, Ren M, King W, ElSalanty M, Zakhary I, Sharawy M, Cui H, Ding HF.

BMC Cancer. 2012 May 29;12:203. doi: 10.1186/1471-2407-12-203.

11.

Aberrant microRNA expression in multiple myeloma.

Dimopoulos K, Gimsing P, Grønbæk K.

Eur J Haematol. 2013 Aug;91(2):95-105. doi: 10.1111/ejh.12124. Epub 2013 Jun 5. Review.

PMID:
23586898
12.

MicroRNA: important player in the pathobiology of multiple myeloma.

Bi C, Chng WJ.

Biomed Res Int. 2014;2014:521586. doi: 10.1155/2014/521586. Epub 2014 Jun 3. Review.

13.

[Molecular pathogenesis of myeloma for the therapeutic targets].

Hanamura I.

Nihon Rinsho. 2007 Dec;65(12):2202-8. Review. Japanese.

PMID:
18069261
14.

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL, Neri A.

Genes Chromosomes Cancer. 2009 Jun;48(6):521-31. doi: 10.1002/gcc.20660.

PMID:
19306352
15.

Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma.

Jernberg-Wiklund H, Nilsson K.

Ups J Med Sci. 2012 May;117(2):166-77. doi: 10.3109/03009734.2012.659293. Epub 2012 Feb 21. Review.

16.

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling.

Gutiérrez NC, Sarasquete ME, Misiewicz-Krzeminska I, Delgado M, De Las Rivas J, Ticona FV, Fermiñán E, Martín-Jiménez P, Chillón C, Risueño A, Hernández JM, García-Sanz R, González M, San Miguel JF.

Leukemia. 2010 Mar;24(3):629-37. doi: 10.1038/leu.2009.274. Epub 2010 Jan 7.

PMID:
20054351
17.

Genetic events in the pathogenesis of multiple myeloma.

Chng WJ, Glebov O, Bergsagel PL, Kuehl WM.

Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96. Review.

18.

MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival.

Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Lawrie CH.

Biol Direct. 2011 May 18;6:23. doi: 10.1186/1745-6150-6-23.

19.

Molecular pathogenesis of multiple myeloma.

Tonon G.

Hematol Oncol Clin North Am. 2007 Dec;21(6):985-1006, vii. Review.

PMID:
17996585
20.

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.

Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM.

Clin Cancer Res. 2007 Jul 1;13(13):3771-5. Review.

Supplemental Content

Support Center